Andere Sprachen Alnylam Pharmaceuticals, Inc.

Aktien

A0CBCK

US02043Q1076

ALNY

Pharmazeutika

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 13.06.2025			% 5 Tage	% 1. Jan.
307,99 ^USD	+1,09 %		-0,00 %	+30,89 %

09.06.	Alnylam Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 09:20 AM
09.06.	Alnylam erhält EU-Zulassung für RNAi-Medikament zur Behandlung von Transthyretin-Amyloidose mit Kardiomyopathie	MT

Andere Sprachen

Alnylam reçoit une approbation de la Commission européenne pour l'AMVUTTRA® (vutrisiran) dans le traitement de la cardiomyopathie amyloïde ATTR	10.06.
Alnylam Gets EU Approval for RNAi Drug to Treat Transthyretin Amyloidosis With Cardiomyopathy	09.06.
Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy	09.06.
Alnylam Receives European Commission Approval for AMVUTTRA®? for the Treatment of ATTR Amyloidosis with Cardiomyopathy	09.06.
Alnylam to Webcast Presentation at Goldman Sachs 46th Annual Global Healthcare Conference	28.05.
Transcode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory Board	28.05.
Alnylam Issues 2024 Corporate Responsibility Report	20.05.
Alnylam Pharmaceuticals : 2024 REPORT	20.05.
Alnylam Pharmaceuticals Insider Sold Shares Worth $3,124,217, According to a Recent SEC Filing	19.05.
AMVUTTRA® (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-B	17.05.
Part II Of MRNA Patent Wars: The Growing Legal Battles Shaping The MRNA Landscape	14.05.
Alnylam Pharmaceuticals, Inc. to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the Helios-B Phase 3 Study Results at Heart Failure 2025 Congress	12.05.
Alnylam To Share Progress Across Its Transthyretin Amyloidosis Franchise Including Additional Analyses Of The Helios-B Phase 3 Study Results At Heart Failure 2025 Congress	12.05.
Alnylam to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the HELIOS-B Phase 3 Study Results at Heart Failure 2025 Congress	12.05.
Alnylam to Webcast Presentation at BofA Securities 2025 Health Care Conference	05.05.
Alnylam Pharmaceuticals : Q1 2025 Earnings Presentation ›	01.05.
Alnylam Q1 Non-GAAP Net Loss Narrows, Revenue Rises	01.05.
Alnylam Pharmaceuticals : Q1 2025 Press Release ›	01.05.
Alnylam Pharmaceuticals : Q1 2025 Presentation ›	01.05.
Alnylam Pharmaceuticals : Q1 2025 GAAP/Non-GAAP Reconciliation ›	01.05.
Alnylam: Q1 Earnings Snapshot	01.05.
Alnylam Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	01.05.
Alnylam Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Period Progress	01.05.
Earnings Flash (ALNY) Alnylam Pharmaceuticals Posts Q1 Revenue $594.2M, vs. FactSet Est of $588.4M	01.05.
(ALNY) Alnylam Pharmaceuticals Sees Fiscal Year 2025 Revenue Range $2.05B - $2.25B	01.05.

Keine Ergebnisse zu dieser Suche

Mehr Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Alnylam Pharmaceuticals, Inc.

Aktien

A0CBCK

US02043Q1076

ALNY

Pharmazeutika

Andere Sprachen

Filter